Scholar Rock Drops Troubled Catalent Facility From FDA Refiling For SMA Drug Apitegromab
Scholar Rock removed Novo Nordisk’s ex-Catalent Indiana manufacturing site from its FDA submission for apitegromab after an FDA inspection classified the plant as “Official Action Indicated.” Scholar Rock will rely on an alternative U.S. fill-finish facility; the PDUFA action date remains Sept. 30, 2026. The Catalent site also affected Incyte’s Zynyz FDA bid.
How this was made
The 30-second read
Why it matters
The FDA’s OAI classification at the Catalent plant forces a submission change to rely solely on an alternative U.S. facility, while the PDUFA action date remains September 30.
Market read
Traders should monitor regulatory and manufacturing quality read-through across CDMO-dependent biotech supply chains, especially when FDA OAI outcomes trigger submission pivots.
What to watch
The article does not quantify how much of apitegromab supply or validation work is affected by the site swap, so actual execution risk could be higher or lower than implied.
Background
Scholar Rock refiled apitegromab in March 2026 using two third-party fill-finish facilities, including a Catalent site; a subsequent April 2026 inspection produced an OAI outcome.
Ticker impact
Scholar Rock withdrew the Catalent fill-finish site from its FDA submission for apitegromab after the FDA issued an Official Action Indicated classification.
Near-term sentiment likely negative on quality/regulatory overhang, partially offset by the unchanged September 30 PDUFA action date.
The article describes a specific FDA enforcement classification (OAI) at the Catalent plant and a submission change, which can pressure risk perception even if the approval timeline remains on track.
Novo Nordisk notified Scholar Rock that the April 2026 Catalent inspection received an Official Action Indicated designation, triggering the withdrawal from the apitegromab submission.
Potentially modest negative bias as investors price broader quality/regulatory disruption tied to the ex-Catalent site.
The article does not state direct financial impact to Novo, but it links the site to multiple programs and an OAI designation, which can still affect perceived manufacturing risk.
Incyte said the Catalent Indiana site is the primary fill-finish manufacturer for commercial Zynyz and that it has not experienced safety or product quality issues.
Likely limited immediate impact because Incyte explicitly states no safety or product quality issues for marketed Zynyz.
The article provides a direct company statement intended to reassure on quality, which can dampen negative read-through from the OAI designation.
Regeneron is pursuing approvals through multiple CDMOs for a prefilled syringe version of Eylea HD to mitigate risks associated with the troubled Indiana plant.
Near-term effect likely neutral to slightly negative, reflecting operational mitigation rather than an announced product failure.
The article frames this as risk mitigation and does not report a specific regulatory action against Regeneron’s product.
Market effects
Highlights fill-finish CDMO quality/regulatory fragility and potential read-across risk for other biologics and specialty drug programs using the same site.
Points to Indiana-based manufacturing scrutiny as a cross-company operational risk factor.
Reinforces that FDA enforcement outcomes can propagate across multinational development and commercial supply chains.
Counterpoint
The unchanged September 30 PDUFA action date suggests the FDA may still be comfortable with the alternative site, limiting downside beyond sentiment.
Key entities
- companyScholar Rock
Withdraws the Catalent facility from its FDA submission for apitegromab after an OAI inspection outcome.
- companyNovo Nordisk
Informs Scholar Rock that the Catalent inspection received an OAI designation, prompting the withdrawal.
- companyCatalent
The Indiana fill-finish plant inherited by Novo Holdings is associated with an FDA OAI classification and Form 483s.
- companyIncyte
States Catalent Indiana is the primary fill-finish for commercial Zynyz and reports no safety or product quality issues.
- companyRegeneron
Mitigates risk for Eylea HD prefilled syringe approvals by using multiple CDMOs.
